HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmet, I. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Ahmet, I. Articles by Matsuda, H.

Ann Thorac Surg 2000;70:901-905
© 2000 The Society of Thoracic Surgeons

---

Original articles: cardiovascular

Myocardial protection using diadenosine tetraphosphate with pharmacological preconditioning

^a First Department of Surgery, Osaka University Medical School, Osaka, Japan
^b First Department of Medicine, Osaka University Medical School, Osaka, Japan

Address reprint requests to: Dr Sawa, First Department of Surgery, Osaka University Medical School, Yamadaoka 2–2, Suita, Osaka 565, Japan
e-mail: ismayilt{at}surg1.med.osaka-u.ac.jp

Background. We have reported a similar cardioprotective effect and mechanism of diadenosine tetraphosphate (AP4A) and ischemic preconditioning in rat hearts. In this study, the applicability of AP4A administration to cardiac surgery was tested by using a canine cardiopulmonary bypass model.

Methods. Hearts underwent 60 minutes of cardioplegic arrest (34°C) by a single dose of cardioplegia. Cardioplegia contained either AP4A (40 µmol/L; n = 6) or saline (n = 6). Beagles were weaned from cardiopulmonary bypass 30 minutes after reperfusion, and left ventricular function was evaluated after another 30 minutes by using the cardiac loop analysis system.

Results. Administration of AP4A significantly improved the postischemic recovery of cardiac function and reduced the leakage of serum creatine kinase compared with saline. Systemic vascular resistance, mean aortic blood pressure, and the electrocardiographic indices were not significantly altered by AP4A administration.

Conclusions. Administration of AP4A was cardioprotective without apparent adverse effects. Because the cardioprotective mechanism may be similar to that of ischemic preconditioning, the addition of AP4A into cardioplegia may be a novel safe method for clinical application of preconditioning cardioprotection.

This article has been cited by other articles:

				S. Melnik, M. Wright, J. A. Tanner, T. Tsintsadze, V. Tsintsadze, A. D. Miller, and N. Lozovaya Diadenosine Polyphosphate Analog Controls Postsynaptic Excitation in CA3-CA1 Synapses via a Nitric Oxide-Dependent Mechanism J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 579 - 588. [Abstract] [Full Text] [PDF]

				J. Luo, V. Jankowski, N. Gungar, J. Neumann, W. Schmitz, W. Zidek, H. Schluter, and J. Jankowski Endogenous Diadenosine Tetraphosphate, Diadenosine Pentaphosphate, and Diadenosine Hexaphosphate in Human Myocardial Tissue Hypertension, May 1, 2004; 43(5): 1055 - 1059. [Abstract] [Full Text] [PDF]

				W. B. Dobkowski Myocardial Protection During Minimally Invasive Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 319 - 324. [Abstract] [PDF]

				M. Shimizu, M. Tamamori-Adachi, H. Arai, N. Tabuchi, H. Tanaka, and M. Sunamori Lipopolysaccharide pretreatment attenuates myocardial infarct size: A possible mechanism involving heat shock protein 70-inhibitory {kappa}B{alpha} complex and attenuation of nuclear factor {kappa}B J. Thorac. Cardiovasc. Surg., November 1, 2002; 124(5): 933 - 941. [Abstract] [Full Text] [PDF]